Method of treating cancer with a VEGF antagonist and an anti-proliferative agent
Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, such as a VEGF trap, an anti-proliferative agent, such as taxol, and a pharmaceutically acceptable carrier.
1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent such that the cancer is treated, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2.
2. The method of claim 1 , wherein the anti-proliferative agent is a microtubule stabilizing agent.
3. The method of claim 2 , wherein the anti-proliferative agent is paclitaxel, or a derivative, analogue, or mixture thereof.
4. The method of claim 1 , wherein the anti-proliferative agent is a platinum-based chemotherapeutic selected from the group consisting of cisplatin, carboplatin, and iproplatin.
5. The method of claim 1 , wherein the subject is a human subject.
6. A method of treating cancer in a subject in need thereof, comprising administering to the subject a vascular endothelial growth factor (VEGF) antagonist and an anti-proliferative agent such that the cancer is treated, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2, and the anti-proliferative agent is a paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.
7. The method of claim 6 , wherein the subject is a human subject.
8. A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent, wherein the growth of the tumor is reduced, and wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2.
9. The method of claim 8 , wherein the anti-proliferative agent is paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.
10. The method of claim 8 , wherein the anti-proliferative agent is a platinum-based chemotherapeutic selected from the group consisting of cisplatin, carboplatin, and iproplatin.
11. A method of reducing ascites formation in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein ascites formation is inhibited, and wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2.
12. The method of claim 11 , wherein administration is subcutaneous or intravenous.
13. A method of inhibiting or reducing tumor growth in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein tumor growth is inhibited, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2, and the anti-proliferative agent is selected from the group consisting of paclitaxel, docetaxel or a derivative, analogue, or mixture of paclitaxel and a platinum-based chemotherapeutic.
14. A method of reducing the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect, comprising administering the chemotherapeutic agent with a VEGF antagonist, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) comprising the amino acid sequence of SEQ ID NO:2.
15. The method of claim 14 , wherein the chemotherapeutic agent is an anti-proliferative agent selected from the group consisting of paclitaxel, or a derivative, analogue, or a mixture of paclitaxel and a platinum-based chemotherapeutic.
16. The method of claim 14 , wherein the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect is reduced by at least 20%.
17. The method of claim 16 , wherein the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect is reduced by about 30-50%.